Integra CEO Jan De Witte to leave

  • After about two years in the position
  • Praise and thanks for De Witte
  • Search for a successor
  • De Witte said 86 words

(exechange) — Princeton, New Jersey, February 28, 2024 — Jan De Witte, chief executive of Integra, is set to leave his position. As announced by Integra LifeSciences Holdings Corp. in a news release and in a regulatory filing published on Wednesday, February 28, 2024, Jan De Witte will leave his post as chief executive officer at the medical technology company, after about two years in the role, effective following the appointment of a successor, which the Company expects to occur by the end of 2024.

Generally speaking, it raises questions when a CEO leaves his post after a short tenure.

Integra will undertake a search for a successor.

The Company also announced that Stuart Essig, Integra’s chairman, has been appointed to the role of executive chairman, effective immediately.

“Personal decision”

The planned management change is explained as follows. Stuart Essig stated: “Jan’s personal decision to retire from Integra and return to Europe follows a leadership tenure marked by significant contributions to the company, including the evolution of our strategy and an expansion of core capabilities.”

Precise information regarding Jan De Witte’s future plans was not immediately available.


Integra said: “Jan De Witte has informed the Board of Directors (the “Board”) of his intention to retire from his position as president and chief executive officer of Integra following the appointment of a successor, which the Company expects to occur by the end of 2024.”

Integra further said: “On February 27, 2024, Jan De Witte informed Integra LifeSciences Holdings Corporation (the “Company”) of his intention to retire from his position as President and Chief Executive Officer and director of the Company following the completion of a succession process.”

“Not because of any disagreement”

Integra stated, regarding the change: “Mr. DeWitte’s plans to retire are for personal reasons and not because of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”

Share price decline since December 2021

The announcement follows a decline in Integra LifeSciences Holdings Corp.’s share price of 29% since December 2021. December 2021 is the month in which De Witte’s tenure as CEO began.

In the position of CEO since 2021

Jan De Witte became CEO of the Company in 2021.

To ensure a smooth transition, De Witte will remain at the Company and continue to serve as President and Chief Executive Officer and as a Board member until the effective date of the Board’s appointment of his successor.

During this time, De Witte will also continue to serve as the principal executive officer of the Company. De Witte is Integra’s President and Chief Executive Officer.

He commenced service as President and Chief Executive Officer and a director in December 2021.

De Witte has an extensive track record in the global healthcare industry spanning more than two decades.

Prior to joining Integra, De Witte served as chief executive officer of Barco N.V. from 2016 to August 2021.

At Barco, he created shareholder value through digital innovation and new product development, commercial acceleration, international market growth and operational excellence.

Prior to Barco, De Witte spent 17 years in senior-level leadership roles at GE, including as president and CEO of GE Global Healthcare IT.

Before GE, De Witte spent five years in strategic consulting at McKinsey and three years in operations at Procter & Gamble.

86 words by Jan De Witte

In the release announcing his planned departure as CEO of Integra LifeSciences Holdings Corp., Jan De Witte received praise and thanks.

In announcing his departure, Jan De Witte said 86 words.

“Incredibly proud”

Jan De Witte stated: “I am incredibly proud of everything we have accomplished together here at Integra. I am grateful to both the Board for their confidence and trust and the talented workforce at Integra for their ongoing passion and dedication to excellence as we endeavor to restore patients’ lives and set new standards of care. I believe strongly in Integra’s potential for future growth and success. In the meantime, we are squarely focused on delivering our objectives for 2024 through operational execution, particularly in our manufacturing and supply chain.”

The above text is an excerpt from the exechange report 10.2024 ($), publication date March 4, 2024.